Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Genotypes
研究概览
简要总结
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
No additional treatment or intervention will be conducted except for blood sampling that will be limited to one time only.
Blood samples (10 cc in volume) will be collected from all study participants once they provided written informed consent form. DNA will be extracted from peripheral blood samples using DNA isolation kit.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study
排除标准
- 未提供
结局指标
主要结局
Genotypes
时间窗: 36months
To define genotypes of HCC and RCC patients who will likely to response to molecular targeted therapy. To define genotypes associated with adverse events from molecular targeted. To identify genotypes which will predict survival or disease-free survival following molecular targeted therapy.
次要结局
未报告次要终点
研究者
Ho Yeong Lim
Professor of Medicine, Sungkyunkwan University School of Medicine, Department of Hematology and Oncology
Samsung Medical Center